MedTrace Logo

A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01037907 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2022-06-03

No results posted yet for this study

Summary

To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with BGC20-0134.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Pleneva TM BGC20-0134

Placebo or 5 g dose

DRUG

Placebo

Placebo or 5 g dose

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Belgium
  • France
  • Germany
  • Poland
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01037907 on ClinicalTrials.gov